SALZBURG THERAPEUTICS is an innovative drug-development company that is developing unique Cytotoxamer® and Genotoxamer® products for cancer treatment. Our technology provides an innovative solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.
The Cytotoxamer® approach simultaneously improves efficacy and reduces the toxicities associated with traditional chemotherapy. The end-result is a longer and a higher quality of life for cancer patients.
The initial focus for product development at Salzburg Therapeutics is a Cytotoxamer® for the treatment of prostate cancer.
Salzburg Therapeutics is also developing F10 and other nucleic acid drugs for treatment of acute myelogenous leukemia (see Pardee et al., Blood. 119:3561-3570 2012; Jennings-Gee et al., Exp Hem 41: 180-188 2013).
Board of Directors
Stan Mandel (Chair)
William H. Gmeiner
William Gmeiner, Ph.D., MBA - CSO
Stan Mandel, Ph.D., MBA - CEO
Scientific Advisory Board
Bayard Powell, MD Chief, Hem/Onc WFSM Comprehensive Cancer Center
Edward Chu, M.D. Deputy Director Pittsburgh Cancer Institute
K.C. Balaji, M.D., Professor/Head VA Urology, WFSM
Waldemar Debinski, M.D., Ph.D. Director, WFUSM Brain Tumor Center of Excellence
Frits Peters, Ph.D., Professor, VU University, Amsterdam
March 2013: K.C. Balaji named to Salzburg Scientific advisory board strengthening expertise in translational prostate cancer research.
January 2012: Bayard Powell, MD joins Salzburg Scientific advisory board. Dr. Powell is an expert in hematological malignancies, reflecting the high priority of leukemias for product development.
November 2010: Salzburg Therapeutics receives grant from Healthcare bill as mentioned in the Triad business journal.
May 2009: Salzburg Therapeutics featured in Triad Business Journal article highlighting innovative cancer-focused therapeutic companies.
April 2009: Salzburg Therapeutics announces completion of a licensing deal with UneMed for the commercial development of oligonucleotides containing FdUMP
October 2008: Salzburg Therapeutics is featured in a Piedmont Triad Business Journal news feature.
May 2008: Salzburg Therapeutics is announced as a Grand Prize Winner in the PTEN Growth Accelerator Program Competition.
April 2008: Salzburg Therapeutics is pleased to announce Waldemar Debinski, M.D., Ph.D., Director of the WFUSM Brain Tumor Center of Excellence and Godefridus J. (Frits) Peters, Ph.D., Professor of Medical Oncology at VU University Medical Center, Amsterdam have joined our scientific advisory board.
January 2008: Salzburg Therapeutics joins the WFU Demon Incubator